Disclaimer
Biotec Pharmacon ASA. Company Head Office: Strandgata 3, N-9008 Tromsø, NORWAY
Telephone: (+47) 7764 8900 – Telefax: (+47) 7764 8901 E-mail: info@biotec.no
NO 959 033 560 MVA
All trademarks, service marks, and trade names of Biotec Pharmacon ASA expressly or indirectly defined as such on the web site are trademarks or registered trademarks of Biotec Pharmacon ASA or its affiliates, unless stated otherwise. You may not use, copy, reproduce, republish, upload, post, transmit, distribute, or modify our trademarks in any way, including, but not limited to, in advertising or publicity pertaining to distribution of materials on our web site, without our prior written consent. The use of our trademarks on any other web site or materials is prohibited without our express written consent. The list of ways to exploit the trademarks is not complete and all other, whether known or unknown, ways of exploitation of the trademarks are also prohibited.
Copyright© 1999-2009 Biotec Pharmacon ASA. The copyright in all content on this web site is owned by Biotec Pharmacon ASA. You may not modify any of the materials and you may not copy, distribute, transmit, display, perform, reproduce, publish, license, create derivative works from, transfer, or sell any of the content. Except as authorized under copyright law, you may not reuse any content without first obtaining the consent of Biotec Pharmacon ASA. The list of ways to exploit the copyrights is not complete and all other, whether known or unknown, ways of exploitation of the copyrights are also prohibited.
Telephone: (+47) 7764 8900 – Telefax: (+47) 7764 8901 E-mail: info@biotec.no
NO 959 033 560 MVA
All trademarks, service marks, and trade names of Biotec Pharmacon ASA expressly or indirectly defined as such on the web site are trademarks or registered trademarks of Biotec Pharmacon ASA or its affiliates, unless stated otherwise. You may not use, copy, reproduce, republish, upload, post, transmit, distribute, or modify our trademarks in any way, including, but not limited to, in advertising or publicity pertaining to distribution of materials on our web site, without our prior written consent. The use of our trademarks on any other web site or materials is prohibited without our express written consent. The list of ways to exploit the trademarks is not complete and all other, whether known or unknown, ways of exploitation of the trademarks are also prohibited.
Copyright© 1999-2009 Biotec Pharmacon ASA. The copyright in all content on this web site is owned by Biotec Pharmacon ASA. You may not modify any of the materials and you may not copy, distribute, transmit, display, perform, reproduce, publish, license, create derivative works from, transfer, or sell any of the content. Except as authorized under copyright law, you may not reuse any content without first obtaining the consent of Biotec Pharmacon ASA. The list of ways to exploit the copyrights is not complete and all other, whether known or unknown, ways of exploitation of the copyrights are also prohibited.
News
- Svein Lien appointed new CEO of Biotec Pharmacon ASAMarch 10,2010Svein Lien has been appointed new CEO of Biotec Pharmacon, following Lars Viksmoen’s decision to resign after 3 years as CEO. Svein Lien will assume the position with effect from 15 March, 2010.
- Biotec Pharmacon presenting re-established platform at BIO-Europe 2010March 09,2010Dr Sven Rohmann presented on behalf of Biotec Pharmacon at BIO-Europe Spring 2010 in Barcelona. The presentation took place at March 9, 12:30, under the AutoImmune/Inflammation Section.
- Testing SBG packaging containers after weak results from oral mucositis study February 22,2010Biotec Pharmacon has received data showing that SBG failed to show superiority over placebo in the phase III study for oral mucositis. Newly available biological activity assays indicate that SBG used in the diabetic ulcer program may have been inactivated as a result of interaction with polyethylene in the product containers. The company plans to carry out accelerated stability studies of SBG with alternative containers.